Download MendeleyAntibodies to distinct epitopes on MPXV enveloped virion provide additive and complete protection.
Zhang, D., Fantin, R.F., Zhu, X., Feng, Z., Park, S.C., Laghlali, G., Clark, J.J., Nobrega, G.M., Kottkamp, A.C., Samanovic, M.I., Mulligan, M.J., Lim, J.K., Schotsaert, M., Yuan, M., Coelho, C.H., Wilson, I.A.(2026) Sci Immunol 11: eaee7011-eaee7011
- PubMed: 42962053 Search on PubMed
- DOI: https://doi.org/10.1126/sciimmunol.aee7011
- Primary Citation Related Structures:
9Z4P, 9Z56, 9Z57, 9Z58, 9Z59, 9Z5A, 9Z5B, 9Z5C, 9Z5D, 9Z5E, 9Z5F, 9Z5G, 9Z5H - PubMed Abstract:
The continuing evolution of monkeypox virus (MPXV) clades capable of sustained human-to-human transmission poses an escalating global health risk, yet no effective therapy exists for poxvirus infection. Here, we investigate a panel of human monoclonal antibodies (mAbs), derived from an antibody library, which targets A35 and B6 antigens located on the extracellular enveloped virion (EV). Four high-affinity mAbs target the central groove of the A35 dimer, whereas one targets a previously unidentified epitope on the A35 protruding loop. Three other mAbs recognize distinct, previously unmapped epitopes on the multidomain B6 antigen. Those epitopes are conserved across most orthopoxviruses. A combination of an anti-A35 and an anti-B6 antibody provides additive and complete protection from both morbidity and mortality in a lethal VACV mouse model, challenging the previous assumption that targeting both the EV and mature virion (MV) forms is required for full protection. These studies uncover critical information for next-generation therapeutics and vaccines against emerging MPXV as well as other Orthopoxvirus threats.
- Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
Organizational Affiliation:
